<DOC>
	<DOCNO>NCT01332552</DOCNO>
	<brief_summary>GSK2485852 Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor develop treatment chronic HCV infection . HBI115040 first administration GSK2485852 human establish initial safety , tolerability , pharmacokinetic , antiviral profile . The study design fusion single repeat dose cohort HCV infect subject evaluate safety , pharmacokinetics , antiviral activity GSK2485852 . HBI115040 describe Phase I , randomize , double-blind , placebo-controlled , dose escalation fusion study determine safety , tolerability , pharmacokinetic , antiviral profile GSK2485852 single dos ( Part 1 ) , repeat dos ( Part 2 ) , ritonavir co-administration ( Part 3 ) chronically infect HCV subject . The study also explore effect moderate ( 30 % ) fat meal pharmacokinetic endpoint HCV subject Part 1 .</brief_summary>
	<brief_title>A First Time Human Study Assess Safety , Tolerability , Pharmacokinetics , Antiviral Activity Single Repeat Doses GSK2485852 Chronically Infected Hepatitis C Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring ( i.e. , ECG ) , include cardiac , pulmonary , hepatic , biliary , gastrointestinal , renal disorder , cancer within past 5 year . Males females 18 65 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential . Body weight &gt; = 50 kg ( 110 lb . ) men &gt; = 45 kg ( 99 lb . ) woman BMI 18.535.0 kg/m2 inclusive allow . Capable give write informed consent , include compliance requirement restriction list consent form . AST , ALT , alkaline phosphatase &lt; 3.0xULN bilirubin &lt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Average QTcB QTcF &lt; 450 msec ; QTcB QTcF &lt; 480 msec subject Bundle Branch Block . Treatment naive chronically infect HCV subject , define infection &gt; 6 month prior HCV therapy , HCV RNA viral load great 100,000 IU/mL HCV genotype 1a 1b . HCV subject mixed genotype eligible study . Positive HCV RNA antiHCV antibody time screen AND positive antiHCV antibody , HCV RNA , HCV genotype least 6 month screen ; OR Positive HCV RNA antiHCV antibody time screen AND liver biopsy within three year prior screen indicate absence cirrhosis . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . A positive prestudy Hepatitis B surface antigen HIV antibody within 3 month screen . A positive prestudy drug/alcohol screen . History regular alcohol consumption within 6 month study . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new investigational product within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . History sensitivity heparin heparininduced thrombocytopenia . Holter monitoring show one following : Any symptomatic arrhythmia ( except isolate extra systole ) ; Sustained cardiac arrhythmia ( atrial fibrillation flutter , SVT ( &gt; 10 consecutive beat ) ) ; Sustained tachycardia &gt; 150 beat per minute ; Nonsustained sustain ventricular tachycardia ( define &gt; 3 consecutive ventricular ectopic beat ) ; Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high awake subject ] , WPW syndrome , preexcitation syndrome ) ; Symptomatic sinus pause sinus pause &gt; 3 second unless patient straining , vomit , type hypervagal response ; 300 supraventricular ectopic beat 24 hour ; 250 ventricular ectopic beat 24 hour ; Ischemia , diagnose sequence ECG change include flat downsloping STsegment depression &gt; 0.1 mV , gradual onset offset last minimum period 1 minute . Each episode ischemia must separate minimum duration least 1 minute , ST segment return back baseline ( 1x1x1 rule ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>First administration human</keyword>
	<keyword>antiviral activity</keyword>
	<keyword>safety</keyword>
	<keyword>hepatitis C</keyword>
</DOC>